Eli Lilly and Co (LLY) Quote

FDA advises LLY it wants AdCom meeting. Portends delay. Meanwhile NVO CEO was interviewed on CNBC-TV this morning, repeats NVO’s PR warning dated in January 2024 that it will not have manufacturing capacity to fill demand for its weight loss drug until 2006(?).

Sell now boys you had a great run

LLY new 52 week high

LLY new 52 week high

Eli Lilly was investigating Talampanel prior to 2010

For the treatment of epilepsy, malignant gliomas and ALS
development codes LY-300164 , LY300164
results from the trial for ALS have been found negative
Talampanel is not currently under development.
It showed effectiveness for epilepsy in clinical trials but its development was suspended due to its poor pharmacokinetic profile, namely a short terminal half-life (3 hours) that necessitated multiple doses per day.
RespireRx Pharmaceuticals $ RSPI a little unknown company KRM–II–81 has shown promising results for Epilepsy.
Has fully suppressed the epileptiform activity in the excised brain tissue from a 19-year-old patient with pharmaco-resistant epilepsy.

I bought Lilly about a year ago based on Mounjaro and knowing it was going to be a success. I am a FAmily Doc who has done bariatric medicine for 30 years. Zepbound definitely is inducing more weight loss than Ozempic (Wegovy) but I am getting concerned over the number of patients that are stopping zepbound / Mounjaro due to side effects, seems a lot more than on Ozempic ( Wegovy) .

Incredible, isn’t it
What gets me about these social media bozos is they actually believe they will become Boca Raton rich by day trading sub $1 stocks
Because they are incapable of researching companies

800$ tomorrow?

LLY new 52=week high

LLY new 52 week high

LLY new 52 week high

LLY new 52 week high

Shorted at 625.

Great news on their new diabetes drug.

Looking for the bottom ,not yet :)

LLY new 52 week high

Amazing financials

Billionaires dream a while back, speculating

Interesting company

Wowwwwwww

Knew this company from the 80 ssssss

LLY new 52 week high

Who is pumping?

LLY new 52 week high

anyone here, hear enzc announced they now have a CURE for hiv/aids clone 3, yesterday on accesswire and yahoo finance.

anyone here, hear enzc announced they now have a CURE for hiv/aids clone 3, yesterday on accesswire and yahoo finance.

anyone here, hear enzc announced they now have a CURE for hiv/aids clone 3, yesterday on accesswire and yahoo finance.

LLY new 52 weewk high

LLY new 52 week high

RSI Moving Average Bullish Cross Over + Gap up with jump in volume.
Check out at - https://www.stockaio.com/US/ai/Stock/LLY/MovingAverage

OTCSC nice post as always.

Let's hope this gets their attention.

RGBP Is A FAR GREATER Fit Than ENZC And Here's Why!


# 1 RGBP has (24+) Disruptive Biotech Patents worth $$ BILLIONS; ENZC has only two (2).

https://patents.google.com/?inventor=David+Koos&sort=new
https://patents.justia.com/assignee/regen-biopharma-inc
https://www.otcmarkets.com/filing/html?id=15088630&guid=dk3wkKwg3iFaJth


# 2 Eli Lilly had prior collaborative arrangement with RGBP with joint I.P. claim on NR2F6 for developing an mRNA Cancer Vaccine

https://www.biospace.com/article/releases/regen-biopharma-enters-into-open-innovation-drug-discovery-program-agreement-with-eli-lilly-/


# 3 Eli Lilly-Curevac 2017 Partnership to develop mRNA Cancer Vaccine FAILED Ending June 2020 due to Curevac's faulty research data. Lilly lost $100 Million in shared development costs. Merger/Acquisition with RGBP is the shortest path to getting back on track!


# 4 Licensing of (1) Patent with (2) INDs (New Drug Applications) for treating pancreatic & colon cancer by mRNA Vaccine; The Future of Medicine

https://www.aamc.org/news-insights/mrna-technology-promises-revolutionize-future-vaccines-and-treatments-cancer-infectious-diseases


# 5 RGBP is in league with Big Pharmas developing mRNA Cancer Vaccines that Eli Lilly clearly wants to be included in, especially in the wake of their failed relationship with Curevac. It is a Trillion Dollar Market!

https://www.ventureradar.com/keyword/Cancer%20Vaccines


# 6 FDA Patent Approval

https://newsinvasion24.com/regen-biopharma-inc-otcmkts-rgbp-gets-approval-for-cancer-vaccine-patent/


# 7 Partnership:Oncology Pharma Paid $1M for Patent Licensing; will now Post Quarterly Revenues for 15 Years


# 8 Certification Audit of RGBP by BRG completed 11/15/21. This is indicative of an Industry Standard Merger/Acquisition


#9 On 4/27/21 CEO files Acquisition Intent with 8K

https://www.otcmarkets.com/filing/conv_pdf?id=14894907&guid=55ywkew26hwfJth


Opinion ONLY

Be well and prosper...

You Mean RGBP

Can someone answered where the 50M dollars of 190k shares sold by LLY insiders went at? Nobody is talking about it in here anymore!!! It’s a mystery the end of such crazy amount went? Has anyone emailed this CEO? Come on!!! Nobody really questioned this? Are expanding? Did insiders bought Lamborghinis with such? We have to know, any volunteers? Do you think this ended up at RGBP? REGEN Biopharma!!! Many people talking about it

New PR on Alzheimers drug for LLY

For educational purposes:

"https://www.otcdynamics.com/lly-lillys-donanemab-slowed-alzheimers-disease-progression-in-phase-2-trial-full-data-presented-at-ad-pd-2021-and-published-in-nejm/"

Sounds positive to me. I note Yahoo Finance does an article and said no improvement on secondary end points. That does not sound right to me. They are talking about 20 to 40 percent improvement in secondary end points. That is still major with a disease that is so devastating. It might also improve with more study IMHO.

Another detailed PR.

"https://flashalert.me/?symbol=LLY&source=PR&referer=https://stocktwits.com/&url=https://www.prnewswire.com:443/news-releases/lillys-donanemab-slowed-alzheimers-disease-progression-in-phase-2-trial-full-data-presented-at-adpd-2021-and-published-in-nejm-301246745.html&s3=LLY/2021-03-13/06-36-06_000000/pr/d11c6c228fcdee2eeac476a5b679a2eb/lillys-donanemab-slowed-alzheimers-disease-progression-in-phase-2-trial-full-data-presented-at-adpd-2021-and-published-in-nejm-301246745.html"

Should get more information on the Monday cc.

Boing X 2

One would think this would garner more attention.

"https://www.govconwire.com/2021/03/eli-lilly-books-2-7b-in-army-contracts-for-coronavirus-antibody-treatment-production"

I had to stumble across this by accident this am.

Boing X 2

Eli Lilly going to by RDGL

just checking it ....ouch



https://wm-no.glb.shawcable.net/service/home/~/?id=78940&part=2&auth=co

News; $LLY Why AstraZeneca, Bristol Myers Squibb, and Eli Lilly Stocks Jumped Today

Shares of several large drugmakers were jumping higher on Wednesday, following the U.S. elections. AstraZeneca (NASDAQ: AZN) stock was up 6.6% as of 3:13 p.m. EST. Shares of Bristol Myers Squibb (NYSE: BMY) weren't too far behind, with a gain of 6.4%. The biggest winner, tho...

Got this from LLY - Why AstraZeneca, Bristol Myers Squibb, and Eli Lilly Stocks Jumped Today

ENZ* would be great fit for Eli Lilly to pair with

Just In: $LLY Effective Antibody Treatments for COVID-19 Could Be Ready Soon

Regeneron Pharmaceuticals (NASDAQ: REGN) and Eli Lilly (NYSE: LLY) are both developing potential new coronavirus treatments that could become available long before any vaccine candidates have a chance to prove themselves safe and effective. In fact, at least one COVID-19...

Got this from LLY - Effective Antibody Treatments for COVID-19 Could Be Ready Soon

$LLY and GILD up nice

Thinking that Anavex 2-73 would fit nicely into Lilly’s portfolio of products for CNS diseases.

News; $LLY Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer

INDIANAPOLIS , Sept. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Verzenio ® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly decreased the risk of breast cancer recurrence by 25 percent compared to standard adjuv...

Find out more LLY - Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer

JUST IN: $LLY Is Blueprint Medicines a Good Biotech Stock to Buy Now?

So far this year, shares of Blueprint Medicines (NASDAQ: BPMC) haven't performed nearly as well as the company's research and development team. The company's already earned FDA approval for two new cancer drugs this year, but the stock is down about 17% this year. Is this a good biotech sto...

In case you are interested LLY - Is Blueprint Medicines a Good Biotech Stock to Buy Now?

Targeting ONTX I hear?

Breakout trade

"CONFIRMED breakout above 164.32
Target: 172.57"

Boing X 2

New here. Hoping for success of the LY-CoV555.

News: $LLY Better Buy: Johnson & Johnson vs. Eli Lilly

Longtime leaders, short-term laggards. That's a quick rundown of how Johnson & Johnson (NYSE: JNJ) and Eli Lilly (NYSE: LLY) stocks have performed. While both big pharma stocks have delivered impressive gains for investors over the long run, they've both turned in disappointing res...

Read the whole news LLY - Better Buy: Johnson & Johnson vs. Eli Lilly

News: $LLY Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

RIDGEFIELD , Conn. and INDIANAPOLIS , Nov. 17, 2019 /PRNewswire/ -- A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that Jardiance® (empagliflozin) was associated wit...

In case you are interested LLY - Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists